• Apogee notified Nasdaq of its merger close, requesting delisting and continued trading halt; shares suspended from trading Sept. 4, 2026.
• Nasdaq to file SEC Form 25 to delist and deregister the stock under Exchange Act Section 12(b).
• Company plans to file SEC Form 15 to terminate registration under Section 12(g), suspending reporting obligations under Sections 13 and 15(d).

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apogee Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-035537), on September 03, 2026, and is solely responsible for the information contained therein.